Regeneron agrees research collaboration with Parabilis Medicines
Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties
Read More
Section: Research
GSK signs agreement with Protas to streamline clinical trials
The new three-year agreement builds on an existing two-year relationship
Read More
Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases
The agreement strengthens Boehringer Ingelheim’s growing immunology pipeline
Read More
AstraZeneca reports positive phase 3 data for tozorakimab in COPD
COPD affects nearly 400 million people globally and is the third leading cause of death worldwide
Read More
AL-S Pharma release new data from AP-101 phase 2 trial for ALS
ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord
Read More